These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19278572)

  • 21. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    Yan SF; Ramasamy R; Schmidt AM
    J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAGE and its ligands in retinal disease.
    Barile GR; Schmidt AM
    Curr Mol Med; 2007 Dec; 7(8):758-65. PubMed ID: 18331234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature.
    Yan SF; Ramasamy R; Schmidt AM
    Circ Res; 2010 Mar; 106(5):842-53. PubMed ID: 20299674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of the receptor for advanced glycation end products (RAGE) in inflammation].
    Mosquera JA
    Invest Clin; 2010 Jun; 51(2):257-68. PubMed ID: 20928981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.
    Clynes R; Moser B; Yan SF; Ramasamy R; Herold K; Schmidt AM
    Curr Mol Med; 2007 Dec; 7(8):743-51. PubMed ID: 18331232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced glycation end products (AGEs) activate mast cells.
    Sick E; Brehin S; André P; Coupin G; Landry Y; Takeda K; Gies JP
    Br J Pharmacol; 2010 Sep; 161(2):442-55. PubMed ID: 20735427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis.
    Bopp C; Bierhaus A; Hofer S; Bouchon A; Nawroth PP; Martin E; Weigand MA
    Crit Care; 2008; 12(1):201. PubMed ID: 18226173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Receptor of advanced glycation endproducts RAGE/AGER: an integrative view for clinical applications].
    Barbezier N; Tessier FJ; Chango A
    Ann Biol Clin (Paris); 2014; 72(6):669-80. PubMed ID: 25486663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond.
    Daffu G; del Pozo CH; O'Shea KM; Ananthakrishnan R; Ramasamy R; Schmidt AM
    Int J Mol Sci; 2013 Oct; 14(10):19891-910. PubMed ID: 24084731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
    Raucci A; Cugusi S; Antonelli A; Barabino SM; Monti L; Bierhaus A; Reiss K; Saftig P; Bianchi ME
    FASEB J; 2008 Oct; 22(10):3716-27. PubMed ID: 18603587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions.
    Han SH; Kim YH; Mook-Jung I
    Mol Cells; 2011 Feb; 31(2):91-7. PubMed ID: 21347704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycation endproducts: from precursors to RAGE: round and round we go.
    Ramasamy R; Yan SF; Schmidt AM
    Amino Acids; 2012 Apr; 42(4):1151-61. PubMed ID: 20957395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation.
    Schmidt AM; Hofmann M; Taguchi A; Yan SD; Stern DM
    Semin Thromb Hemost; 2000; 26(5):485-93. PubMed ID: 11129404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders.
    Hudson BI; Bucciarelli LG; Wendt T; Sakaguchi T; Lalla E; Qu W; Lu Y; Lee L; Stern DM; Naka Y; Ramasamy R; Yan SD; Yan SF; D'Agati V; Schmidt AM
    Arch Biochem Biophys; 2003 Nov; 419(1):80-8. PubMed ID: 14568011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biology of the receptor for advanced glycation end products and its ligands.
    Schmidt AM; Yan SD; Yan SF; Stern DM
    Biochim Biophys Acta; 2000 Dec; 1498(2-3):99-111. PubMed ID: 11108954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity.
    Teismann P; Sathe K; Bierhaus A; Leng L; Martin HL; Bucala R; Weigle B; Nawroth PP; Schulz JB
    Neurobiol Aging; 2012 Oct; 33(10):2478-90. PubMed ID: 22227007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.